13 December 2024
Kromek Group
plc
("Kromek"
or the "Group")
Result of
AGM
Kromek (AIM: KMK), a leading developer of radiation
and bio-detection technology solutions for the advanced imaging and
CBRN detection segments, announces that at its annual general
meeting ("AGM"), held earlier today, all resolutions were duly
passed.
Details of the proxy voting results, which
should be read alongside the Notice of AGM, are below:
Resolution
|
Votes for*
|
Votes
against
|
Votes
withheld
|
Total proxy
votes
|
|
No. of
votes
|
% of votes
cast**
|
No. of
votes
|
% of votes
cast**
|
No. of
votes
|
|
1
|
207,344,859
|
93.58
|
14,216,844
|
6.42
|
214,790
|
221,776,493
|
2
|
219,607,384
|
99.44
|
1,240,099
|
0.56
|
929,010
|
221,776,493
|
3
|
218,684,712
|
99.50
|
1,093,449
|
0.50
|
1,998,332
|
221,776,493
|
4
|
219,546,698
|
99.64
|
784,563
|
0.36
|
1,445,232
|
221,776,493
|
5
|
217,710,854
|
98.85
|
2,543,519
|
1.15
|
1,522,120
|
221,776,493
|
6
|
202,085,251
|
91.31
|
19,229,668
|
8.69
|
670,309
|
221,985,228
|
7
|
208,955,888
|
94.64
|
11,827,699
|
5.36
|
992,906
|
221,776,493
|
*Includes discretionary
votes
**Excludes withheld votes
For further
information, please contact:
Kromek Group
plc
|
|
Arnab Basu, CEO
Paul Farquhar,
CFO
|
+44 (0)1740 626 060
|
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
|
|
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate
Finance
Tim Redfern - ECM
Michael Johnson/Tamar Cranford-Smith - Sales
|
+44 (0)20
7220 0500
|
Gracechurch Group
(Financial PR)
|
|
Harry Chathli/Claire Norbury/Henry
Gamble
|
+44 (0)20 4582 3500
|
Kromek Group
plc
Kromek Group plc is a leading developer of radiation
detection and bio-detection technology solutions for the advanced
imaging and CBRN detection segments. Headquartered in County
Durham, UK, Kromek has manufacturing operations in the UK and US,
delivering on the vision of enhancing the quality of life through
innovative detection technology
solutions.
The advanced imaging segment comprises the medical
(including CT and SPECT), security and industrial markets. Kromek
provides its OEM customers with detector components, based on its
core cadmium zinc telluride (CZT) platform, to enable better
detection of diseases such as cancer and Alzheimer's, contamination
in industrial manufacture and explosives in aviation
settings.
In CBRN detection, the Group provides nuclear
radiation detection solutions to the global homeland defence and
security market. Kromek's compact, handheld, high-performance
radiation detectors, based on advanced scintillation and
solid-state readout technology, are primarily used to protect
critical infrastructure, events, personnel and urban environments
from the threat of 'dirty bombs'.